Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 30+ AI models, with 0% extra fees
Why NeoGenomics (NEO) Shares Are Falling Today
Why NeoGenomics (NEO) Shares Are Falling Today
Why NeoGenomics (NEO) Shares Are Falling Today
Anthony Lee
Thu, February 19, 2026 at 5:55 AM GMT+9 2 min read
In this article:
NEO
-10.31%
What Happened?
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 10.1% in the afternoon session after the company reported fourth-quarter results that beat expectations but issued a full-year 2026 forecast that fell short of analyst predictions.
While NeoGenomics’ fourth-quarter revenue grew 11% to $190 million, beating Wall Street’s estimates, investors appeared more concerned with the company’s outlook. The guidance for full-year 2026 adjusted earnings per share and adjusted EBITDA both came in below analyst consensus. Adding to the concerns, the full-year 2025 results showed a 37% increase in net loss to $108 million, even as revenue grew. The weaker-than-expected forecast seemed to overshadow the strong quarterly performance, prompting a negative reaction from the market.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy NeoGenomics? Access our full analysis report here, it’s free.
What Is The Market Telling Us
NeoGenomics’s shares are extremely volatile and have had 39 moves greater than 5% over the last year. But moves this big are rare even for NeoGenomics and indicate this news significantly impacted the market’s perception of the business.
The biggest move we wrote about over the last year was 10 months ago when the stock dropped 34.8% on the news that the company reported disappointing first-quarter 2025 earnings as sales fell below Wall Street’s expectations. Another blemish was that while full-year revenue guidance was raised, full-year EBITDA guidance was maintained, signaling that profit margins for the year would be lower than initially expected. On the other hand, NeoGenomics beat analysts’ EPS expectations, and its full-year revenue guidance exceeded Wall Street’s estimates. Overall, this quarter was mixed. The areas below expectations seemed to be driving the move.
NeoGenomics is down 13% since the beginning of the year, and at $10.23 per share, it is trading 22.6% below its 52-week high of $13.22 from January 2026. Investors who bought $1,000 worth of NeoGenomics’s shares 5 years ago would now be looking at an investment worth $180.08.
Microsoft, Alphabet, Coca-Cola, Monster Beverage—all began as under-the-radar growth stories riding a massive trend. We’ve identified the next one: a profitable AI semiconductor play Wall Street is still overlooking.Go here for access to our full report, it’s free.
Terms and Privacy Policy
Privacy Dashboard
More Info